Pembrolizumab-Induced Giant Cell Arteritis in the Setting of Urothelial Carcinoma

被引:3
|
作者
Miano, Deanna Ingrassia [1 ,2 ]
Cosgrove, Ryan [1 ,2 ]
Sherman, Joshua [3 ]
Balaraman, Savitha [4 ]
Sherman, Michael [1 ,2 ]
机构
[1] Ascension Macomb Oakland Hosp, Ascension Eye Inst, Dept Ophthalmol, Warren, MI 48093 USA
[2] Michigan State Univ, Dept Neurol & Ophthalmol, E Lansing, MI 48824 USA
[3] Michigan State Univ, Lyman Briggs Coll, E Lansing, MI 48824 USA
[4] Beaumont Hlth, Dept Oncol, Royal Oak, MI USA
关键词
Pembrolizumab; giant cell arteritis; vision loss; oncology; UVEITIS;
D O I
10.1080/01658107.2022.2108847
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A 65-year-old male presented to the Ophthalmology clinic with painless loss of vision in his right eye. Over the previous week the right eye's vision had progressed from being blurry to complete loss. Three weeks prior to presentation he had begun treatment with pembrolizumab for urothelial carcinoma. Ophthalmological assessment and subsequent imaging prompted further investigation, and a temporal artery biopsy confirmed a diagnosis of giant cell arteritis. This case demonstrates a rare, yet serious, condition of biopsy-confirmed giant cell arteritis in the setting of pembrolizumab treatment for urothelial carcinoma. In addition to reporting a vision threatening side effect of pembrolizumab we emphasise the need for vigilant care of patients on this drug as symptomatology and laboratory results may be inconspicuous.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 50 条
  • [41] Pembrolizumab-induced acquired perforating dermatosis
    Gu, Yaron
    de Silva, Dinuke
    Henderson, Christopher J. A.
    Sebaratnam, Deshan F.
    JEADV CLINICAL PRACTICE, 2024, 3 (05): : 1611 - 1614
  • [42] Pembrolizumab-Induced Sarcoidosis: A Case Report
    Walmsley, C. S.
    Sibert, T.
    Summers, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [43] A Case of Pembrolizumab-Induced Respiratory Failure
    Hornick, A.
    Tackett, S.
    Hejal, R. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [44] Pembrolizumab-induced type 1 diabetes
    Maia, Ariana
    Soares, Daniela M.
    Azevedo, Sofia
    Pereira, Teresa
    Amaral, Claudia
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (06) : 1118 - 1121
  • [45] Pembrolizumab-induced neuromuscular overlap syndrome
    Sousa Fernandes, C.
    Reigota, C.
    Lemos, J.
    Negrao, L.
    Batista, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 736 - 736
  • [46] Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab-induced myositis
    Bertold, Clemence
    Troin, Laura
    Chassang, Madleen
    Passeron, Thierry
    Doyen, Jerome
    Montaudie, Henri
    Picard-Gauci, Alexandra
    JEADV CLINICAL PRACTICE, 2023, 2 (04): : 940 - 943
  • [47] Pembrolizumab-Induced Toxic Epidermal Necrolysis
    Borg, Luca
    Buhagiar, Malcolm
    La Ferla, Elisa
    Pisani, David
    Said, Janabel
    Boffa, Michael J.
    CASE REPORTS IN ONCOLOGY, 2022, 15 (03): : 887 - 893
  • [48] Pembrolizumab-Induced Ocular Myasthenic Crisis
    Lorenzo, Christian T.
    Fitzpatrick, Haley
    Campdesuner, Victoria
    George, Justin
    Lattanzio, Natalia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (07)
  • [49] Pembrolizumab-induced Eosinophilic Gastrointestinal Disorders
    Nakamura, Masakatsu
    Otsuka, Toshimi
    Kumagai, Motona
    Arisawa, Tomiyasu
    INTERNAL MEDICINE, 2022, 61 (02) : 267 - 269
  • [50] Pembrolizumab-Induced Gastritis: A Call for Recognition
    Alp, Jameel
    Karna, Rahul
    Amin, Khalid
    Sloan, Joshua A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S3155 - S3155